Images List Premium Download Classic

Leukemia

Leukemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
The Regents Of The University Of California
September 14, 2017 - N°20170260236

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory t cells (treg) populations; for treating or ameliorating a vascular inflammation, and kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion ...
Antagonism of the vip signaling pathway
Emory University
September 14, 2017 - N°20170258904

Inhibition of the vip signaling pathway with vip antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a vip antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood ...
Methods for treating cancers
Emory University
September 14, 2017 - N°20170258804

Or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for detecting bcr-abl inhibitor resistance-related mutation and data acquisition method for predicting bcr-abl inhibitor ...
Yamaguchi University
September 07, 2017 - N°20170253932

An object of the present invention is to detect a mutation related to bcr-abl inhibitor resistance with high accuracy for chronic myelogenous leukemia or the like. A method for detecting the mutation comprises the steps of: amplifying a region including a fusion site and a mutation site related to bcr-abl inhibitor resistance contained in a bcr-abl fusion gene using a ...
Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
Mor Research Applications Ltd.
September 07, 2017 - N°20170252364

Provided herein are compositions for treatment of acute lymphoblastic leukemia (all) and methods of their use, including inhibiting all relapse. Further provided herein are systems of treatment that are directed by a health care provider, and which combine prognostic methods for determining all relapse and the described treatments.
Compositions containing ibrutinib
Janssen Pharmaceutica Nv
September 07, 2017 - N°20170252344

Discussed herein are pharmaceutical compositions containing ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, b-cell proliferative disorders such as non-hodgkin lymphoma (diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These ...
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies
The Regents Of The University Of California
August 31, 2017 - N°20170247446

The present invention provides method of treating a k-ras-expressing cancer in a subject comprising administering to the subject a therapeutic amount of an agent that antagonizes leukemia inhibitory factor (lif). Compositions and kits for treating a k-ras-expressing cancer in a subject are also provided.
Compositions and methods of aloe polysaccharides
Bespoke Bioscience, Llc
August 31, 2017 - N°20170246199

The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and ...
Methods and pharmaceutical compositions for treating lymphoid malignancy
The Trustees Of Columbia University In The City Of New York
August 31, 2017 - N°20170246173

The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (pten) gene, or t-cell acute lymphoblastic leukemia (t-all). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (pi3kδ) inhibitor and a phosphoinositide 3-kinase-gamma (...
Method for producing gamma delta t cells, and pharmaceutical thereof
Medinet Co., Ltd.
August 24, 2017 - N°20170240859

The purpose of the present invention is to provide a method for producing γδt cells with which it is possible to obtain a cell population including a large amount of γδt cells and including virtually no cells infected by human t-cell leukemia virus (htlv) even when pbmcs derived from a person infected ...
Modulating gamma-c-cytokine activity
Bioniz, Llc
August 24, 2017 - N°20170240607

Peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting γc-cytokine activity involve raising ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
August 24, 2017 - N°20170240529

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as pancreatic cancer, prostate cancer, ...
Uses of hypoxia-inducible factor inhibitors
Oncoimmune, Inc.
August 24, 2017 - N°20170239315

The present invention relates to treating a hematologic cancer using a hypoxia-inducible factor (hif inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the hif inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (csc) using the hif inhibitor.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Thiazolyl-containing compounds for treating proliferative diseases
Dana-farber Cancer Institute, Inc.
August 17, 2017 - N°20170233411

The present disclosure provides thiazolyl-containing compounds of formula (i), (ii), or (iii). The compounds described herein may be able to inhibit protein kinases (e. G., src family kinases (e. G., hemopoietic cell kinase (hck)), bruton's tyrosine kinase (btk)) and may be useful in treating and/or preventing proliferative diseases (e. G., myelodysplasia, leukemia, lymphoma (e. G., waldenstrom's macroglobulinemia)) and in ...
Cancer therapeutics
University Of Virginia Patent Foundation
August 17, 2017 - N°20170233375

This invention relates to compounds that bind to wild-type cbfβ and inhibit cbfβ binding to runx proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type cbfβ from runx1 in cells, change occupancy of runx1 on target genes, and alter gene ...
Kinase inhibitors
University Of Virginia Patent Foundation
August 17, 2017 - N°20170231975

The disclosed molecules are inhibitors of bcr-abl and src kinases. The molecules are cytotoxic to gleevec resistant cells. Inhibitors of bcr-abl and src kinases are used in the treatment of chronic myelogenous leukemia among other diseases.
Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and ...
Amderma Pharmaceuticals, Llc
August 17, 2017 - N°20170231932

The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition ...
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
Kalobios Pharmaceuticals, Inc.
August 10, 2017 - N°20170226227

The invention provides methods and compositions comprising anti-epha3 antibodies for the treatment of myeloproliferative disorders.
Ror1 specific multi-chain chimeric antigen receptor
Cellectis
August 10, 2017 - N°20170226183

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen ror1. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ror1. The alpha, beta and gamma polypeptides composing these cars are designed to assemble in juxtamembrane position, ...
N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and ...
Pimco 2664 Limited
August 03, 2017 - N°20170217881

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e. G., diseases) including, inflammation and/or joint destruction ...
A nucleoside derivative for use as a drug, particularly for the treatment of chronic lymphocytic ...
Instytut Biologii Medycznej Polskiej Akademii Nauk
August 03, 2017 - N°20170216340

We disclose nucleoside derivatives useful as drugs, particularly for the treatment of chronic lymphocytic leukemia.
Loading